Clinical Trial Update: An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis [Phase 2]

View source ↗

Summary

Extension study of MOM-M281-004 (M281) in generalized myasthenia gravis terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• MOM-M281-004 extension study (M281) (M281)

Snippet

Sponsor: Momenta Pharmaceuticals, Inc. | Conditions: Generalized Myasthenia Gravis | Phase 2 | Status: TERMINATED | Results posted: 2022-02-16